内科理论与实践

内科理论与实践 >

2023 , Vol. 18 >Issue 04: 234 - 238

DOI: https://doi.org/10.16138/j.1673-6087.2023.04.004

专家论坛

肾上腺皮质癌临床与基础研究

展开
  • 上海交通大学医学院附属瑞金医院内分泌代谢科 上海市内分泌代谢病研究所 国家代谢性疾病临床医学研究中心（上海） 国家卫健委内分泌代谢病重点实验室 上海市内分泌肿瘤重点实验室，上海 200025

收稿日期: 2023-06-15

  网络出版日期: 2024-01-09

基金资助

上海市卫生健康委员会卫生行业临床研究专项(20224Y0088)

收起

Clinical and basic research on adrenal cortical carcinoma

Expand

Received date: 2023-06-15

  Online published: 2024-01-09

Fold

本文引用格式

武鲁铭, 王卫庆 . 肾上腺皮质癌临床与基础研究[J]. 内科理论与实践, 2023 , 18(04) : 234 -238 . DOI: 10.16138/j.1673-6087.2023.04.004

参考文献

[1] Fassnacht M, Tsagarakis S, Terzolo M, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors[J]. Eur J Endocrinol, 2023, 189(1): G1-G42.
[2] Rodriguez-Galindo C, Krailo MD, Pinto EM, et al. Treatment of pediatric adrenocortical carcinoma with surgery, retroperitoneal lymph node dissection, and chemotherapy: the Children’s Oncology Group ARAR0332 protocol[J]. J Clin Oncol, 2021, 39(22): 2463-2473.
[3] Crona J, Beuschlein F. Adrenocortical carcinoma-towards genomics guided clinical care[J]. Nat Rev Endocrinol, 2019, 15(9): 548-560.
[4] Raj N, Zheng Y, Kelly V, et al. PD-1 blockade in advanced adrenocortical carcinoma[J]. J Clin Oncol, 2020, 38(1): 71-80.
[5] Assié G, Jouinot A, Fassnacht M, et al. Value of molecular classification for prognostic assessment of adrenocortical carcinoma[J]. JAMA Oncol, 2019, 5(10): 1440-1447.
[6] Fassnacht M, Assie G, Baudin E, et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2020, 31(11): 1476-1490.
[7] Cavlan D, Bharwani N, Grossman A. Androgen- and estrogen-secreting adrenal cancers[J]. Semin Oncol, 2010, 37(6): 638-648.
[8] Staubitz WJ, Oberkircher OJ, Lent MH, et al. Feminization in an adult male with adrenal cortical carcinoma[J]. N Y State J Med, 1954, 54(18): 2565-2572.
[9] Moreno S, Guillermo M, Decoulx M, et al. Feminizing adreno-cortical carcinomas in male adults[J]. Ann Endocrinol (Paris), 2006, 67(1): 32-38.
[10] Gabrilove JL, Sharma DC, Wotiz HH, et al. Feminizing adrenocortical tumors in the male[J]. Medicine (Baltimore), 1965, 44: 37-79.
[11] Barnard L, Schiffer L, Louw du-Toit R, et al. 11-oxygenated estrogens are a novel class of human estrogens but do not contribute to the circulating estrogen pool[J]. Endocrinology, 2021, 162(3): bqaa231.
[12] Yokoyama M, Kijima T, Takada-Owada A, et al. A case of estrogen-secreting adrenocortical carcinoma[J]. IJU Case Rep, 2021, 4(5): 318-321.
[13] Mamoojee Y, Ganguri M, Taylor N, et al. Clinical case seminar: postmenopausal androgen excess-challenges in diagnostic work-up and management of ovarian thecosis[J]. Clin Endocrinol (Oxf), 2018, 88(1): 13-20.
[14] Goto T, Murakami O, Sato F, et al. Oestrogen producing adrenocortical adenoma: clinical, biochemical and immunohistochemical studies[J]. Clin Endocrinol(Oxf), 1996, 45(5): 643-648.
[15] Tezuka Y, Yamazaki Y, Ono Y, et al. Unique sex steroid profiles in estrogen-producing adrenocortical adenoma associated with bilateral hyperaldosteronism[J]. J Endocr Soc, 2020, 4(2): bvaa004.
[16] Mermejo LM, Carvalho FG, Molina CAF, et al. Estrogen-secreting adrenocortical tumor in a postmenopausal woman[J]. Endocrinol Diabetes Metab Case Rep, 2021, 2021: 20-0214.
[17] Wu L, Xie J, Jiang L, et al. Feminizing adrenocortical carcinoma: the source of estrogen production and the role of adrenal-gonadal dedifferentiation[J]. J Clin Endocrinol Metab, 2018, 103(10): 3706-3713.
[18] Fujisawa Y, Sakaguchi K, Ono H, et al. Combined steroidogenic characters of fetal adrenal and Leydig cells in childhood adrenocortical carcinoma[J]. J Steroid Biochem Mol Biol, 2016, 159: 86-93.
[19] Schr?der MAM, Sweep FCGJ, van Herwaarden AE, et al. Transcriptional comparison of testicular adrenal rest tumors with fetal and adult tissues[J]. Eur J Endocrinol, 2022, 187(5): 607-615.
[20] Greenhill C. Adrenal gland: the genetics of adrenocortical carcinoma revealed[J]. Nat Rev Endocrinol, 2016, 12(8): 433.
[21] Zheng S, Cherniack AD, Dewal N, et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma[J]. Cancer Cell, 2016, 29(5): 723-736.
[22] Wu L, Xie J, Qi Y, et al. Mutational landscape of non-functional adrenocortical adenomas[J]. Endocr Relat Cancer, 2022, 29(9): 521-532.
[23] Lerario AM, Mohan DR, Hammer GD. Update on biology and genomics of adrenocortical carcinomas: rationale for emerging therapies[J]. Endocr Rev, 2022, 43(6): 1051-1073.
[24] Libé R, Borget I, Ronchi CL, et al. Prognostic factors in stage Ⅲ-Ⅳ adrenocortical carcinomas(ACC)[J]. Ann Oncol, 2015, 26: 2119-2125.
[25] Roca E, Berruti A, Sbiera S, et al. Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer[J]. Endocr Relat Cancer, 2017, 24(7): 319-327.
[26] Wilmouth JJ Jr, Olabe J, Garcia-Garcia D, et al. Sexually dimorphic activation of innate antitumor immunity prevents adrenocortical carcinoma development[J]. Sci Adv, 2022, 8(41): eadd0422.
[27] Pearlstein SS, Conroy PC, Menut KC, et al. Evaluation of necrosis as a diagnostic and prognostic indicator in adrenocortical carcinoma[J]. JAMA Surg, 2021, 156(12): 1173-1174.
[28] Nazha B, Zhuang TZ, Dada HI, et al. Blood-based next-generation sequencing in adrenocortical carcinoma[J]. Oncologist, 2022, 27(6): 462-468.
[29] Relav L, Doghman-Bouguerra M, Ruggiero C, et al. Steroidogenic factor 1, a goldilocks transcription factor from adrenocortical organogenesis to malignancy[J]. Int J Mol Sci, 2023, 24(4): 3585.
[30] Catalano R, Giardino E, Treppiedi D, et al. The cytoskeleton actin binding protein filamin A impairs both IGF2 mitogenic effects and the efficacy of IGF1R inhibitors in adrenocortical cancer cells[J]. Cancer Lett, 2021, 497: 77-88.
[31] Elhassan YS, Altieri B, Berhane S, et al. S-GRAS score for prognostic classification of adrenocortical carcinoma[J]. Eur J Endocrinol, 2021, 186(1): 25-36.
[32] Mohan DR, Lerario AM, Else T, et al. Targeted assessment of G0S2 methylation identifies a rapidly recurrent, routinely fatal molecular subtype of adrenocortical carcinoma[J]. Clin Cancer Res, 2019, 25(11): 3276-3288.
[33] Gara SK, Lack J, Zhang L, et al. Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors[J]. Nat Commun, 2018, 9(1): 4172.
[34] Kerdivel G, Amrouche F, Calmejane MA, et al. DNA hypermethylation driven by DNMT1 and DNMT3A favors tumor immune escape contributing to the aggressiveness of adrenocortical carcinoma[J]. Clin Epigenetics, 2023, 15(1): 121.
Options
文章导航

/

〈 〉